US-based Verve Medical has reported the treatment of the first patient in its pilot trial for uncontrolled hypertension with a renal pelvic denervation (RPD) device. The double-blinded, randomised trial follows positive outcomes from the Tarenting feasibility trial. The initial procedure was conducted by the University of Minnesota and M Health Fairview associate professor and endourology fellowship director, Dr Michael Borofsky. The RPD therapy targets overactive renal nerves, which are significant contributors to high blood pressure. The pilot trial will include 60 participants at ten US clinical sites.